Evidence map›Paper›PMID 39040162›Full record

ArticlemedRxiv : the preprint server for health sciences2024

Detecting HRD in whole-genome and whole-exome sequenced breast and ovarian cancers.

Ammal Abbasi, Christopher D Steele, Erik N Bergstrom, Azhar Khandekar, Akanksha Farswan, Rana R Mckay, Nischalan Pillay, Ludmil B Alexandrov

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Ammal AbbasiDepartment of Cellular and Molecular Medicine, UC San Diego, La Jolla, CA, 92093, USA.
Christopher D SteeleDepartment of Cellular and Molecular Medicine, UC San Diego, La Jolla, CA, 92093, USA.
Erik N BergstromDepartment of Cellular and Molecular Medicine, UC San Diego, La Jolla, CA, 92093, USA.
Azhar KhandekarDepartment of Cellular and Molecular Medicine, UC San Diego, La Jolla, CA, 92093, USA.
Akanksha FarswanResearch Department of Pathology, Cancer Institute, University College London, London, WC1E 6BT, UK.
Rana R MckayMoores Cancer Center, UC San Diego, La Jolla, CA, 92037, USA.
Nischalan PillayResearch Department of Pathology, Cancer Institute, University College London, London, WC1E 6BT, UK.
Ludmil B AlexandrovDepartment of Cellular and Molecular Medicine, UC San Diego, La Jolla, CA, 92093, USA.ORCID 0000-0003-3596-4515

Funding

Detecting Mutational Signatures of Environmental Mutagens in Heathy Individuals for Personalized Cancer PreventionR01ES032547 · NIEHS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ALEXANDROV, LUDMIL B · 2021 to 2025
$3.4M
Mutational Signatures of a Combined Environmental Exposure: Arsenic and Ultraviolet RadiationR01ES030993 · NIEHS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI HUDSON, LAURIE G, LIU, KE JIAN · 2020 to 2024
$2.5M
Comprehensive identification of germline-somatic interactionsR01CA269919 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Ludmil B Alexandrov, Hannah Kathryn Carter · 2022 to 2026
$2.2M
NCI NIH HHS R01 CA269919NIEHS NIH HHS R01 ES030993NIEHS NIH HHS R01 ES032547
6 · The paper itself

Abstract

Breast and ovarian cancers harboring homologous recombination deficiency (HRD) are sensitive to PARP inhibitors and platinum chemotherapy. Conventionally, detecting HRD involves screening for defects in

Identifiers

PMID39040162
PMCPMC11261949

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.